CD8A and neoplasm: LF‐Pan/JQ1 lipos could be considered a dual‐target therapy to boost the tumor immune response, repolarize TAMs, recruit tumor effector CD8+ T‐cell infiltration, and suppress angiogenesis and glucose metabolism, thereby remodeling the tumor immune microenvironment.